BGP Company Profiles - Data/BGP Table of Biggest For-Profit Companies

	2006 Revenue ($m)	Headquarters	Primary Outputs	Instances of Commons-based approaches
Amgen	14268	Thousand Oaks, California	ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline	Amgen - marketing and R&D collaborations with (Powell pp. 72): ARRIS, Envirogen, Glycomex, Guilford, Interneuron, Regeneron, and Zynaxis. these companies develop the product that Amgen later produces and markets. Perhaps there are instances of commons-like sharing here. Further investigation needed
Genentech	9284	South San Francisco	synthetic human insulin - their first famous product, many others produced using the Boyer-Cohen rDNA process	?
Genzyme	3187	Cambridge, Massachusetts	Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue	?
Gilead Sciences	3026	Foster City, California	11 commercial products	?
Biogen Idec	2683	Cambridge, Massachusetts	Treatments for Crohn's disease, non-Hodgkin's lymphoma, and multiple sclerosis	Biogen outsources analyzing clinical trial data to other research labs (Powell pp. 72). Perhaps some of these exhibit commons-like behavior
Cephalon	1764	Frazer, Pennsylvania	Specializes in treating neurodegenerative diseases	?
MedImmune	1277	Gaithersburg, Maryland	Only major drug prevents respiratory diseases in infants	?
Celgene	899	Summit, New Jersey	treatments for erythema nodosum leprosum ("ENL") and multiple myeloma	?
Abraxis BioScience	766	Los Angeles, California	uses patented nanoparticle technology to produce products for metastatic breast cancer	?
ImClone Systems	678	New York, New York	acquired by Eli Lilly, tried to produce Erbitux for Colorectal Cancer, but failed to win FDA approval	?

Navigation

IP_Profile_of_Biggest_for-profit_companies_in_BGP

Company	Revenue in 2006 (USD millions)	R&D in 2006 (USD millions)	Net income/ (loss) in 2006 (USD millions)	Employees in 2006	% of US GDP
Amgen	14268	3366	2950	20100	0.00108
Genentech	9284	1773	2113	10533	0.00070